Company Number: 14114625

Analysis Date: 2025-07-20 16:56 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Regenerative Cell Therapy Consulting Limited is a micro-entity with limited operating history since incorporation in 2022. The company exhibits positive net assets and working capital, indicating a basic ability to meet short-term obligations. However, the presence of significant long-term creditors (£54k) relative to total net assets (£10.6k) suggests some leverage and potential liquidity constraints. Given the company’s niche biotechnology and consultancy activities and sole ownership by an experienced director, credit can be extended with conditions such as monitoring cash flow closely and requiring updated financials periodically.

2. Financial Strength:
   The balance sheet shows modest fixed assets (£1.1k) and current assets (£76k), mainly cash or equivalents, which supports liquidity. Net current assets of approximately £66k provide a healthy short-term buffer. However, long-term creditors of £54k create a sizeable liability burden relative to shareholder equity (£10.6k), implying financial leverage and reliance on external financing. The equity base has nearly doubled from £5.5k in 2023 to £10.6k in 2024, reflecting some retained earnings or capital injections. Overall, financial strength is acceptable for a micro-entity but limited in absolute terms.

3. Cash Flow Assessment:
   Current liabilities due within one year are £15.7k, comfortably covered by current assets, illustrating adequate liquidity to meet immediate obligations. Prepayments and accrued income increased, which may indicate advance receipts or timing differences in revenue recognition. The company operates with only one employee, suggesting low fixed overheads. The relatively high long-term creditor figure should be scrutinized for repayment terms and impact on future cash flow. No explicit cash flow statement is provided, so cash flow projections and covenant compliance should be monitored.

4. Monitoring Points:

• Track the repayment schedule and terms of long-term creditors to assess refinancing or liquidity risks.
• Review updated annual accounts and cash flow statements to confirm the company’s ability to generate sustainable cash inflows.
• Monitor working capital trends, particularly any decline in net current assets that could impair short-term liquidity.
• Assess impact of business developments in biotechnology sector and any regulatory or market risks affecting revenue.
• Confirm continuity of key management and sole shareholder involvement to ensure stable governance.